Bilthoven Biologicals leases GMP production facility to Batavia Biosciences
Bilthoven, (November 21, 2023) – Bilthoven Biologicals (BBio), and Batavia Biosciences (Batavia), entered into a collaboration earlier this year whereby Batavia is manufacturing viral vaccines and viral vectors in a cGMP manufacturing facility (“Amalia facility”) from BBio.
Batavia and BBio announce the release of ‘Amalia,’ a GMP-ready manufacturing facility in Bilthoven, Netherlands. This strategic achievement is enabling the manufacturing of viral vaccines and viral vectors by Batavia at BBio facilities to meet the growing demand for high-quality clinical manufacturing and epidemic preparedness.
Combining this collaboration with the vaccine manufacturing operations of BBio and the EU Pandemic Preparedness project, that was awarded to BBio earlier this year, BBio shapes itself a future as a partner for viral vaccine and viral vector. Within the EU Pandemic Preparedness project BBio creates an ‘ever-warm’ vaccine manufacturing facility to supply viral vector vaccine doses in times of health crisis.
“The collaboration with Batavia is an extension of an existing relationship between Bilthoven Biologicals and Batavia and supports the manufacturing of Batavia’s clinical and commercial pipeline,” said Jef de Clercq, CEO of Bilthoven Biologicals.
“This collaboration shows the ability and flexibility of BBio to partner with other vaccine companies. BBio is uniquely positioned to grow new partnerships based on its broad expertise with viral vaccine manufacturing operations at Utrecht Science Park Bilthoven,” said Jorrit van Hoorn, responsible for Corporate Development at Bilthoven Biologicals.
BBio is a Netherlands-based end-to-end vaccine manufacturer of viral and bacterial vaccines. The company has a long-standing track record in supplying vaccines to European markets and global health partners such as UNICEF, PAHO and WHO/GAVI. With the manufacturing of polio vaccines, BBio is key contributor to the worldwide program to eradicate polio. BBio is also acting as contract manufacturer of vaccines used as cancer treatment, which is registered and supplied to the European market for the treatment of bladder cancer.
BBio is a carve-out of the former Netherlands Vaccine Institute and was acquired by Serum Institute of India in 2012 and employs a little over 500 people. BBio is covering the full vaccine manufacturing value chain with its facilities in Bilthoven on Utrecht Science Park Bilthoven.